<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03825731</url>
  </required_header>
  <id_info>
    <org_study_id>PGC0003</org_study_id>
    <nct_id>NCT03825731</nct_id>
  </id_info>
  <brief_title>A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</brief_title>
  <official_title>A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an early, open, single-centered trial. The aim of this study is to evaluate the
      safety and tolerance of GC022 CAR-T cell immunotherapy in relapsed or refractory B-ALL. The
      investigators plan to include 20 subjects to receive GC022 therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">September 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Dose Limiting Toxicity</measure>
    <time_frame>12 weeks</time_frame>
    <description>A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the GC022 cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>After GC022 infusion, adverse events will be graded as CTCAE 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GC022 persistence</measure>
    <time_frame>12 weeks</time_frame>
    <description>After GC022 infusion, GC022 CAR copies in peripheral blood. bone marrow and CSF will be measured by qPCR in 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percents of Patients with best response as complete remission and MRD negative complete remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Response rates will be estimated as the percents of patients whose best response is complete remission and MRD negative complete remission</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>GC022</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC022</intervention_name>
    <description>GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.</description>
    <arm_group_label>GC022</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory paediatric B-cell ALL 1) 2nd or greater bone marrow (BM)
             relapse or 2) Relapse after remission for the first time in 12 months or 3) The
             interval between relapse after allogeneic hematopoietic stem cell transplantation and
             CAR-T cells transfusion≥100 days or 4) Primary refractory as defined by not achieving
             a CR after 2 cycles of a standard chemotherapy regimen or chemorefractory as defined
             by not achieving a CR after 1 cycle of standard chemotherapy for relapsed leukaemia or
             5) Patients with Philadelphia chromosome positive ALL were eligible if they were
             intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or
             if TKI therapy was contraindicated or 6) Ineligible for allogeneic SCT because of: i.
             Comorbid disease ii. Other contraindications to allogeneic SCT conditioning regimen
             iii. Lack of suitable donor iv. Prior SCT v. Declined allogeneic SCT as a therapeutic
             option after documented discussion, including expected outcomes, about the role of SCT
             with a BM transplantation physician not part of the study team

          2. For relapsed patients, CD19 tumour expression demonstrated in bone marrow or
             peripheral blood by flow cytometry within 3 months of study entry

          3. Aged 2-70 years

          4. Eastern cooperative oncology group (ECOG) performance status of 0 to 2

          5. Life expectancy≥12 weeks

          6. Adequate organ function defined as:1) Creatinine clearance (as estimated by Cockcroft
             Gault) ＞60 mL/min. 2) Serum ALT/AST＜2.5 ULN. 3) Total bilirubin＜1.5 mg/dl, except in
             subjects with Gilbert's syndrome. 4) Cardiac ejection fraction≥45%, no evidence of
             pericardial effusion as determined by an ECHO, and no clinically significant ECG
             findings. 5) No clinically significant pleural effusion. 6) Baseline oxygen saturation
             &gt;92% on room air. 7) pulmonary function: ventilation function is normal or is
             restricted mildly.

          7. Females of reproductive age must be in non-lactation period. Females of childbearing
             potential must have a negative serum or urine pregnancy test. All subjects must use
             medical-approved-contraception (such as intrauterine device and contraceptive drugs)
             during the period of trial and in 6 months after cell transfusion therapy.

          8. The subject agree to and sign informed consent form, willing and able to comply with
             the planned visit, research, treatment planning, laboratory and other test procedures.

        Exclusion Criteria:

          1. Isolated extra-medullary disease relapse;

          2. Patients with Burkitt's lymphoma/leukaemia;

          3. Central nervous system leukemia involved CNS3;

          4. Concomitant malignancy other than non-melanoma skin cancer or adequately-treated
             cervical carcinoma in situ or prostate cancer (PSA score＜1.0) or adequately-treated
             low grade bladder cancer or surgery-cured ductal carcinoma in situ or diagnosis of
             other malignancy exceeds 5 years without relapse or treatment during the 5 years;

          5. Concomitant genetic diseases except Down syndrome;

          6. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb
             positive with HBV DNA copies positive(≥ 5×10^2 copies/ml); RPR+TPPA postive;

          7. Live vaccine ≤4 weeks prior to apheresis;

          8. Presence of grade 2 to 4 graft-versus-host disease (GVHD) after allo-HSCT;

          9. The following medications were excluded: 1) Steroids: Therapeutic systemic doses of
             steroids must be stopped &gt;72 hours prior to tisagenlecleucel infusion. However, the
             following physiological replacement doses of steroids are allowed: &lt;12 mg/m^2/day
             hydrocortisone or equivalent; 2) Allogeneic cellular therapy: Any donor lymphocyte
             infusions must be completed &gt;6 weeks prior to tisagenlecleucel infusion; 3) GVHD
             therapies: Any systemic drug used for GVHD must be stopped &gt;4 weeks prior to infusion
             to confirm that GVHD recurrence is not observed;

         10. Preventive treatments of CNS diseases must be stopped ＞3 days prior to infusion (e.g.,
             intrathecal injection of methotrexate) 1) Radiotherapy of non-CNS nidus must be
             completed ＞2 weeks prior to infusion; 2) CNS stereotactic radiotherapy must be
             completed ＞8 weeks prior to infusion;

         11. ≥2 grade toxicities related to previous therapy are not relieved, with the exception
             of adverse events without security risk (e.g., alopecia);

         12. Known life-threatening allergy, hypersensitivity or intolerance to GC022 cells and
             adjuvant, including DMSO (see investigator's brochure);

         13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren
             syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel
             disease) receive immunosuppressive therapy in 4 weeks before inclusion. thyroid
             hormone replacement therapy is an exception;

         14. For patients that underwent major surgical operation before CAR-T treatment, or
             anticipated to undergo a major surgical operation during the study process, they need
             to be fully recovered and clinically stable before inclusion.

         15. Participate in other clinical trial and received study drugs ＜28 days prior to
             inclusion;

         16. Concomitant disease that may or severe medical condition that may affect patients'
             safety, including active viral or bacterial infection, uncontrollable systemic fungal
             infection, uncontrollable cardiac disease, hypertension, abuse of psychoactive drugs,
             et al.

         17. Any other condition that may increase subjects' risk or interfere with trial's
             results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peihua Lu, PhD&amp;MD</last_name>
      <phone>+86-0316-3306393</phone>
      <email>Peihua_lu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

